Coptisine

• Target:

  LDLR|||Indoleamine 2,3-Dioxygenase (IDO) |||IDO

• Related Pathways:

  Metabolism

• Purity:

  0.9991

• Bioactivity:

  1. Coptisine (Coptisin) treatment increases cell viability based on its reversal effect on the enhanced activity of Indoleamine 2, 3-dioxygenase . 2. Coptisine treats myocardial I/R likely through suppressing myocardial apoptosis and inflammation by inhibiting the Rho/ROCK pathway. 3. Coptisine is a potential anti-osteosarcoma drug candidate, via exerting a strong anti-osteosarcoma effect with very low toxicity . 4. Coptisine with a high dosage could inhibit cholesterol synthesis via suppressing the HMGCR expression and promoting the use and excretion of cholesterol via up-regulating LDLR and CYP7A1 expression. 5. Coptisine suppresses adhesion, migration and invasion of MDA-MB-231 breast cancer cells in vitro, the down-regulation of MMP-9 in combination with the increase of TIMP-1 possibly contributing to the anti-metastatic function for breast cancer.

• Smiles:

  C1=2C=3C(=CC4=C(C3)OCO4)CC[N+]1=CC=5C(C2)=CC=C6C5OCO6

• Molecular Formula:

  C19H14NO4

• Molecular Weight:

  320.32

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  3486-66-6